GlassScriptPhysician profile
David M Cutler
NPI 1255368338
$8,677.93
in general payments reported to CMS, 2019-2025
19 companies · $563 in 2025
The $563 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $847 · 2020: $528 · 2021: $222 · 2022: $188 · 2023: $5,830 · 2024: $501 · 2025: $563.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,600 · Food and Beverage: $1,272 · Education: $21.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,600.00 |
| Food and Beverage | $1,272.39 |
| Education | $21.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $5,841.16 | 2019-2025 | |
| Amgen INC. | $1,176.63 | 2019-2025 | Evenity, Prolia |
| Novo Nordisk INC | $362.53 | 2019-2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $263.59 | 2019-2025 | Zepbound, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $252.07 | 2019-2025 | Fasenra, Breztri |
| Gilead Sciences, INC. | $216.78 | 2019-2025 | Descovy, Veklury |
| Harmony Biosciences LLC | $168.50 | 2020 | |
| Ucb, INC. | $76.08 | 2021 | |
| Glaxosmithkline, LLC. | $50.82 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Bayer Healthcare Pharmaceuticals INC. | $44.40 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $39.92 | 2022 | |
| Almirall LLC | $36.21 | 2022 | |
| Novartis Pharmaceuticals Corporation | $30.01 | 2024 | |
| Sanofi-Aventis U.S. LLC | $23.79 | 2024 | |
| Sumitomo Pharma America, INC. | $21.38 | 2025 | Gemtesa |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Metuchen Pharmaceuticals | $20.90 | 2020 | |
| Vertiflex, INC. | $18.12 | 2019 | |
| Janssen Scientific Affairs, LLC | $18.04 | 2020 | |
| Shire North American Group INC | $17.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Cutler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.